A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy

This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18
together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell
transplant in treating patients with neuroblastoma. Monoclonal antibodies, such as Ch14.18,
may find tumor cells and help kill them. Colony-stimulating factors, such as sargramostim,
may increase the number of immune cells found in bone marrow or peripheral blood. Aldesleukin
may stimulate the white blood cells to kill tumor cells. Isotretinoin may help neuroblastoma
cells become more like normal cells, and to grow and spread more slowly. Giving monoclonal
antibody Ch14.18 with sargramostim, aldesleukin, and isotretinoin after autologous stem cell
transplant may be an effective treatment for neuroblastoma.